Raj Kannan, Aerie Pharmaceuticals CEO
August 23, 2022 07:28 AM EDTUpdated 07:40 AM
Deals
R&D

Al­con, No­var­tis' for­mer eye dis­ease unit, con­tin­ues deal­mak­ing spree with $770M Aerie ac­qui­si­tion

Max Gelman

Senior Editor

Af­ter pick­ing up two drugs from a Bob Langer spin­out in a deal ear­li­er this year, Al­con is stay­ing busy.

The for­mer No­var­tis sub­sidiary fo­cused …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times